Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals positive developments: confident revenue guidance, strategic sales team expansion, and promising product launches like Precise MRD and FirstGene. Despite Q1 losses, management's focus on profitability and growth, coupled with a strong hereditary cancer segment, indicates a positive outlook. The market cap suggests moderate sensitivity, supporting a 'Positive' prediction of a 2% to 8% stock price increase over the next two weeks.
Key Financial Performance
Revenue $200.4 million in Q1 2026, representing 2% growth year-over-year. Growth driven by hereditary cancer testing and mental health testing, offset by declines in prenatal health.
Hereditary Cancer Testing Volume 14% year-over-year growth in Q1 2026, driven by strong demand in unaffected populations and solid execution.
GeneSight Revenue $38.3 million in Q1 2026, up 24% year-over-year. Growth attributed to improved reimbursement trends, payer coverage, and increased ordering provider base.
Prenatal Health Revenue $41.9 million in Q1 2026, down 15% year-over-year. Decline due to disruption from a new ordering system and impact on large accounts.
Gross Margin 68.7% in Q1 2026, up approximately 20 basis points year-over-year. Improvement due to favorable product mix shift.
Adjusted EBITDA Loss of $5 million in Q1 2026, attributed to accelerated commercial growth investments.
Adjusted EPS Loss of $0.09 in Q1 2026, within guidance range.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Precise MRD for breast cancer: Launched in March for select customers. Early feedback indicates satisfaction with test quality and turnaround time. Plans to expand to colorectal and renal cancer in Q3 2026.
AI-enhanced Prolaris prostate cancer test: On track for launch in June 2026. Combines AI, biomarker, germline, and genomic insights.
FirstGene prenatal test: Early access clinical testing ongoing. Full commercial launch planned for the second half of 2026. Differentiated by simultaneous screening capabilities and industry-leading turnaround time.
Expanded MyRisk hereditary cancer panels: Recently launched disease-specific panels to strengthen market position.
Hereditary cancer testing: Volume grew 14% year-over-year, with stronger growth in the unaffected population. Continued market share gains.
GeneSight mental health test: Revenue grew 24% year-over-year with 7% volume growth. Record high of over 39,000 ordering clinicians.
Prenatal health business: Revenue declined 15% year-over-year but showed signs of stabilization. CIGNA updated policy to cover expanded carrier screening panels.
Commercial team expansion: Added over 100 account executives, particularly in oncology, to increase market share and support new product launches.
Operational efficiency in MRD testing: MRD assay demonstrated robust performance with competitive turnaround times.
Improved reimbursement trends: Positive impact of biomarker legislation and payer coverage for GeneSight mental health test.
Cancer Care Continuum prioritization: Significant investments in commercial capabilities and R&D for cancer screening and diagnosis.
Simplified organizational structure: Implemented new decision-making processes and reduced layers to improve agility and customer service.
Focus on profitable growth: Reaffirmed 2026 financial guidance with plans for sequential revenue growth and positive adjusted EBITDA.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Prenatal Health Business Decline: The prenatal health business faced a 15% year-over-year revenue decline in Q1 due to disruptions from a new ordering system and the impact on several large accounts. This poses a challenge to stabilizing and growing this segment.
Weather Impact: Adverse weather conditions in the Northeast and Midwest caused slowdowns in the first couple of months of Q1, though the overall impact was marginal.
Operational Efficiency Challenges: Early feedback from the Precise MRD alpha launch highlighted areas for improvement in customer experience, such as simplifying ordering processes and clarifying sample shipment instructions.
Profitability Pressure: The company reported an adjusted EBITDA loss of $4.5 million in Q1, reflecting the financial strain of significant strategic investments in commercial expansion and R&D.
Market Competition: The company faces competitive pressures in the prostate cancer testing market, requiring investments in commercial channels and new product launches to regain market share.
Regulatory and Reimbursement Risks: The company’s financial performance is influenced by reimbursement trends and payer coverage, particularly for GeneSight and other tests. While there have been improvements, ongoing payer dynamics remain a risk.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Sequential revenue growth in the low single digits is expected in the second quarter of 2026, with acceleration through the remaining quarters. Full-year revenue guidance is reaffirmed at $860 million to $880 million.
Adjusted EBITDA: The company reaffirms its positive adjusted EBITDA target range of $37 million to $49 million for 2026.
Gross Margin: Gross margin is expected to remain strong at 68% to 69% for the full year 2026.
Hereditary Cancer Testing: Continued double-digit growth is expected, driven by strong market position, commercial execution, and innovation. The MyRisk hereditary cancer test remains a cornerstone of growth.
Mental Health Testing (GeneSight): GeneSight is expected to continue delivering growth, supported by improved reimbursement trends and payer coverage. The company plans to extend its reimbursement playbook to the cancer screening portfolio.
Prenatal Testing: Prenatal volume is expected to return to positive growth in the second half of 2026, supported by the launch of FirstGene and ongoing customer engagement.
Product Launches: Key launches include the AI-enhanced Prolaris prostate cancer test in June 2026, Precise MRD for colorectal and renal cancers in Q3 2026, and the full commercial launch of FirstGene in the second half of 2026.
Commercial Investments: $35 million is being invested over several years to expand commercial capabilities, including adding over 100 account executives and enhancing demand generation tools.
Market Trends: The MRD market is in a formative stage, with significant potential for growth as clinical evidence builds. Myriad is well-positioned to serve this market, particularly in community oncology.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the revenue ramp expectation for the second half of the year?
A:Management is confident in achieving revenue guidance for the year, supported by growth in hereditary cancer, GeneSight performance, and expected improvement in the prenatal business. They also highlighted the contributions from 100 newly hired sales team members who are being trained and prepared.
Q:How does the company plan to balance investment in new launches with maintaining adjusted EBITDA profitability?
A:The company is timing investments carefully, focusing on hiring experienced sales team members, market activation, awareness, and clinical studies for MRD. They are committed to staying within profitability guidance while driving growth.
Q:What contributed to the strength in the hereditary cancer business?
A:The hereditary cancer business saw 10% volume growth in the affected market and 16% in the unaffected market. The updated MyRisk panel with 63 genes and the launch of disease-specific panels for breast, prostate, ovarian, and colorectal cancer contributed to this strength. The dedicated sales force for the unaffected market was not reflected in Q1 numbers but is expected to support future growth.
Q:Why was the launch of Precise MRD for colorectal and renal cancer pulled forward to Q3?
A:The launch was accelerated due to interest from community oncologists who wanted to use the test for multiple cancer indications. Management believes they can manage the rollout while maintaining profitability and gaining insights into serving multiple indications in oncology practices.
Q:What updates were provided on the commercial side, including sales team expansion and productivity?
A:The company expanded its sales team by 100 members, focusing on the Cancer Care Continuum. Sales teams are now dedicated to specific portfolios, such as prenatal and hereditary cancer. Productivity is expected to ramp up over several quarters, with some impact anticipated in the back half of the year.
Q:What is the company's high-level view of its portfolio and focus areas?
A:The company is prioritizing the Cancer Care Continuum, aiming to expand beyond hereditary cancer testing. They are managing with discipline and considering partnerships or acquisitions to strengthen their position in this area. AI-enabled products like Prolaris for prostate cancer are key milestones.
Q:How is the company positioning the AI-enabled Prolaris prostate cancer test?
A:The AI-enabled Prolaris test will replace the current Prolaris test, offering enhanced value, particularly in the active surveillance setting. The company is not expecting incremental reimbursement initially but has received positive feedback from clinicians.
Q:What is the outlook for GeneSight revenue and payer dynamics?
A:GeneSight has shown improvement in ASP for several quarters, leveraging policy changes and updated coverage positions. Q1 ASP is considered a baseline for future growth, and management is optimistic about building on this.
Q:What is the outlook for the prenatal business, including the impact of FirstGene?
A:Prenatal volumes were softer than expected in Q1, but management is confident in returning to growth due to a dedicated sales team and the launch of FirstGene. FirstGene is expected to differentiate the company in the market and reengage lost accounts while expanding the market.
Q:What are the expected operating expenses (OpEx) trends for the year?
A:Operating expenses are expected to phase into the year, with management committed to profitable growth. Q1 expenses will require some adjustments in the back half of the year to meet adjusted EBITDA guidance.
Q:What is the reimbursement and gross margin outlook for FirstGene?
A:FirstGene will initially use existing codes, with potential for specific reimbursement codes in the future. It is expected to be accretive to prenatal ASP and gross margins, despite slightly higher costs due to its lab process.
Q:How is the sales team distributed across different product lines?
A:The majority of the 100 new sales team members are focused on the Cancer Care Continuum, including hereditary cancer, MRD, and prostate cancer. The company has been deliberate in aligning resources with growth opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the split of the 100 new sales team members across product lines, only stating that the majority are focused on the Cancer Care Continuum. Additionally, they did not provide granular details on the expected productivity timeline for the new hires or the exact financial impact of FirstGene on prenatal ASPs and gross margins.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Cancer Care
Care Continuum
FirstGene
GeneSight
Precise MRD
account
alpha
biomarker
breast
cancer testing
capability launch
care
category
clinician
commentary
community
confidence
customer
demand
digit
disease
engagement
expansion
experience
health
input
investment Cancer
market
number
patient
plan
portfolio
position
product
sale
share
term
volume
MYGN Transcript
Myriad Genetics, Inc. (MYGN) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call reveals positive developments: confident revenue guidance, strategic sales team expansion, and promising product launches like Precise MRD and FirstGene. Despite Q1 losses, management's focus on profitability and growth, coupled with a strong hereditary cancer segment, indicates a positive outlook. The market cap suggests moderate sensitivity, supporting a 'Positive' prediction of a 2% to 8% stock price increase over the next two weeks.
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call highlighted strong financial performance with a 10% revenue increase and improved margins. Strategic initiatives, including new product launches and market expansion, are expected to drive future growth. No negative market conditions or risks were mentioned, and the company projects improved operating margins. Although there were no shareholder return programs, the overall outlook is optimistic, especially with a market cap of $2.2 billion, indicating a likely positive stock reaction.
Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call reveals strong performance with raised revenue and EBITDA guidance, new product launches, and strategic partnerships. Despite some operational challenges, management's optimistic outlook, particularly in prenatal and cancer diagnostics, suggests potential growth. The Q&A highlights market expansion and improved customer workflows, reinforcing positive sentiment. However, unclear responses on ASP assumptions and reimbursement timelines introduce some uncertainty, slightly tempering the overall positive outlook.
MYGN Slides
Myriad Genetics Q4 2025 slides: profitability improves, MRD launch ahead2026-02-23
Myriad Genetics Q3 2025 slides: volume growth offsets revenue decline, CCC strategy advances2025-11-03
Myriad Genetics Q2 2025 slides: revenue growth accelerates, guidance raised2025-08-05
Myriad Genetics Q1 2025 slides: Revenue declines 3% as company slashes guidance2025-05-06
MYGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
